Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same author

Effect of Nominal-Volume ("Double Tap") Postdilatation on Significant THV Mid-Stent Frame Underexpansion After Balloon-Expandable TAVR.

JACC. Cardiovascular interventions·2026
Same author

On-Table LM View to Predict Left Main Obstruction in TAV-in-TAV.

JACC. Cardiovascular interventions·2026
Same author

In vivo recovery and in vitro quality assessment of apheresis red blood cells stored for 42 days in non-DEHP disposable sets.

Vox sanguinis·2026
Same author

Tubule and microbranch variations in human dentine: A quantitative 3D study with serial block-face scanning electron microscopy.

Journal of microscopy·2026
Same author

Automated Referral Prompts Reveal Lack of Equitable Access to Care in Patients With Aortic Stenosis.

Structural heart : the journal of the Heart Team·2026
Same journal

Should eligibility for medication therapy management be based on drug adherence?

Journal of managed care pharmacy : JMCP·2014
Same journal

Medication adherence in a sample of elderly suffering from hypertension: evaluating the influence of illness perceptions, treatment beliefs, and illness burden.

Journal of managed care pharmacy : JMCP·2014
Same journal

Pharmacists' role in the care of patients with heart failure: review and future evolution.

Journal of managed care pharmacy : JMCP·2014
Same journal

PCMHs, ACOs, and medication management: lessons learned from early research partnerships.

Journal of managed care pharmacy : JMCP·2014
Same journal

Adherence to national recommendations for safe methotrexate dispensing in community pharmacies.

Journal of managed care pharmacy : JMCP·2014
Same journal

Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.

Journal of managed care pharmacy : JMCP·2014
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Introduction: multiple myeloma.

Richard Cook1

  • 1Clinical and Quality Programs, Pharmacy Services, Blue Care Network of Michigan, Grand Rapids, MI 49516, USA. rcook1@bcbsm.com

Journal of Managed Care Pharmacy : JMCP
|November 1, 2008
PubMed
Summary
This summary is machine-generated.

Multiple myeloma (MM) is a primary bone tumor impacting many. Advancements in understanding MM and personalized treatments are improving patient outcomes and quality of life.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Jul 2, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Oncology
  • Hematology
  • Genetics

Background:

  • Multiple myeloma (MM) is the most common primary bone tumor in the U.S., affecting approximately 50,000 individuals.
  • While not currently curable, MM is transitioning from a terminal illness to a manageable chronic condition due to treatment advancements.

Purpose of the Study:

  • To assess the prevalence of multiple myeloma (MM).
  • To provide an overview of the costs associated with MM treatment.

Main Methods:

  • Personalized treatment strategies based on patient age, health status, symptoms, and lab results.
  • Utilizing advancements in diagnostic technology, including cytogenetic testing, to tailor therapies.
  • Leveraging a deeper understanding of MM pathogenesis and the role of genetic mutations.

Main Results:

  • Treatment goals include disease eradication, preventing organ damage, preserving function and quality of life, pain relief, and managing remission.
  • Tailored treatment approaches are leading to better response rates and longer remission periods.
  • Novel agents and therapeutic options are emerging due to improved understanding of MM pathophysiology.

Conclusions:

  • Individualized treatment plans are crucial for optimizing outcomes in multiple myeloma.
  • Understanding the role of cytogenetics and pathophysiology guides the development of new therapies.
  • Balancing treatment costs with survival benefits and quality of life requires further research, including head-to-head studies.